Data Visualization7 min readUpdated 2026-04-03

    GLP-1 Weight Loss Timeline: Week-by-Week Visual Guide from Day 1 to Month 12

    Visual timeline showing what to expect each week and month on GLP-1 medications. Weight loss milestones, side effect patterns, and body changes mapped out.

    Timeline Summary

    Appetite reduction begins within days. Visible weight loss by month 1. Others notice by month 2-3. Major transformation by month 6. Goal weight approach by month 12. Based on averages from semaglutide and tirzepatide clinical data.

    Your GLP-1 Journey Timeline

    Week 1-2

    1-3 lbs

    Reduced appetite, less food noise, possible mild nausea

    First injection, beginning of change

    Month 1

    4-8 lbs (3-4%)

    Smaller portions feel satisfying, sugar cravings decrease, energy improving

    Clothes feel slightly looser

    Month 2

    8-14 lbs (5-7%)

    First dose increase, face looking slimmer, better sleep

    Others may start noticing

    Month 3

    14-22 lbs (7-11%)

    Significant wardrobe changes needed, improved labs, more energy

    Visible transformation

    Month 6

    25-40 lbs (12-20%)

    Major health improvements, reduced medications possible, new body shape

    Life-changing results

    Month 12

    35-55 lbs (17-27%)

    Near or at goal weight, metabolic reset, maintenance phase begins

    New baseline established

    Weight loss ranges based on a 200-lb starting weight using semaglutide or tirzepatide. Individual results vary based on starting weight, dose, diet, exercise, and individual response. Tirzepatide users tend toward the higher end of ranges.

    Side Effect Timeline

    Weeks 1-4

    Peak

    Nausea most common. Adjusting to medication. Mild GI symptoms.

    Weeks 5-12

    Moderate

    Symptoms diminishing. Brief recurrence at dose increases. Body adapting.

    Month 4+

    Minimal

    Most patients report few to no side effects at stable dose.

    Medical Disclaimer: This timeline represents averages from clinical data. Individual experiences vary significantly. Consult your healthcare provider for personalized expectations.

    Frequently Asked Questions

    When will I start losing weight on GLP-1?

    Most patients notice reduced appetite within the first week and measurable weight loss by week 2-4. The first 4 weeks typically produce 2-5 pounds of loss, primarily from reduced caloric intake and water weight. Significant fat loss accelerates from month 2 onward.

    What happens each month on GLP-1?

    Month 1: appetite reduction, 3-5% loss. Month 2-3: dose increases, accelerated loss, 6-10%. Month 4-6: peak velocity, 10-15%. Month 7-9: continued loss, 15-20%. Month 10-12: approaching plateau, 18-25% total. Individual timelines vary.

    When do side effects peak?

    Side effects typically peak during the first 2-4 weeks at each new dose level. The initial starting dose usually produces the most noticeable nausea, which resolves within 1-2 weeks for most patients. Each subsequent dose increase may cause brief recurrence.

    When will other people notice my weight loss?

    Most people notice visible changes in others at around 10% body weight loss, which typically occurs around months 2-3 on GLP-1. Face gains (reduced facial puffiness) often appear earlier. Clothing changes are usually noticeable by month 2.

    Start Your Timeline Today

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 3, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Complete guide covering affordable telehealth weight loss programs in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at up

    Clinician-reviewed guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares.

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    Complete guide covering GLP-1 medications with the fewest GI side effects in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredient

    Start your GLP-1 journey — from $99/mo

    Get Started